Juvenile Fasciitis (Fascial Fibromatosis) - Symptoms, Causes, Treatment & Prevention

Key points:

• Incidence is estimated at 0.03–0.05 cases per 100,000 children per year, making it an uncommon pediatric condition.^{[1] CDC, 2023}
• There is no clear gender predominance, though some series report a slight male excess (≈55%).^{[2] Mayo Clinic, 2022}
• Most lesions develop in the extremities (especially the thigh and forearm) but can occur on the trunk, head/neck, or intra‑abdominal fascia.

Symptoms

Symptoms vary with tumor size, location, and growth rate. Because the mass is non‑malignant, systemic signs (fever, weight loss) are usually absent.

Local signs

• Firm, painless lump – the hallmark sign; often noticed as a swelling that does not fluctuate with activity.
• Gradual enlargement – the tumor may double in size over months; rapid growth can occur during growth spurts.
• Restriction of movement – when the mass is near a joint, it can limit range of motion.
• Skin changes – overlying skin may appear stretched, erythematous, or develop a violaceous hue if the lesion is superficial.
• Pain or tenderness – uncommon but may happen if the tumor presses on a nerve or muscle.

Systemic signs (rare)

• Low‑grade fever – usually only if secondary infection occurs.
• Unexplained fatigue – may be related to chronic pain or reduced activity.

Causes and Risk Factors

The exact cause of juvenile fasciitis remains unknown, but current research points toward a combination of genetic and environmental factors.

Genetic factors

• β‑catenin (CTNNB1) mutations – found in up to 80% of sporadic cases; these mutations lead to uncontrolled fibroblast proliferation.^{[3] NIH, 2021}
• Familial adenomatous polyposis (FAP) – children with FAP may develop desmoid‑type fibromatosis due to APC gene mutations; this variant is called Gardner syndrome.^{[4] Cleveland Clinic, 2022}

Environmental / acquired factors

• Previous trauma or surgery – the disease can arise at sites of previous injury, suggesting a wound‑healing dysregulation.
• Hormonal influence – estrogen appears to stimulate tumor growth; this explains a higher recurrence rate after puberty and the occasional use of anti‑estrogen therapy.

Risk groups

• Children with known CTNNB1 or APC mutations.
• Kids who have undergone orthopedic procedures or suffered deep soft‑tissue injuries.
• Adolescents undergoing rapid growth phases, where hormonal changes may promote tumor expansion.

Diagnosis

Diagnosing juvenile fasciitis requires a step‑wise approach that combines clinical evaluation with imaging and tissue analysis.

1. Clinical examination

• Detailed history: onset, growth pattern, prior injuries, family history of FAP.
• Physical exam: assessment of size, consistency, fixation to underlying structures, and neurovascular status.

2. Imaging studies

• Ultrasound – first‑line for superficial lesions; shows a hypoechoic, well‑defined mass with possible internal vascularity.
• MRI (Magnetic Resonance Imaging) – gold standard for depth, extent, and relationship to muscles/ nerves. Typical findings: low to intermediate signal on T1, heterogeneous high signal on T2, and moderate enhancement after gadolinium.
• CT scan – reserved for deep or intra‑abdominal lesions where MRI is contraindicated.

3. Tissue diagnosis

Because imaging cannot definitively rule out malignancy, a core‑needle or incisional biopsy is usually performed.

• Histopathology – spindle‑shaped fibroblasts arranged in fascicles with a collagenous stroma; low mitotic activity and absence of necrosis.
• Immunohistochemistry – positive for β‑catenin nuclear staining; negative for S‑100 (helps differentiate from nerve sheath tumors).
• Genetic testing – PCR or sequencing for CTNNB1 and APC mutations guides therapy and surveillance.

4. Staging (when needed)

While the disease does not metastasize, staging assesses local spread to plan surgery or radiation.

Treatment Options

Treatment is individualized based on tumor size, location, symptoms, potential functional impairment, and patient/family preferences. A multidisciplinary team—pediatric surgeon, orthopedic oncologist, radiologist, and geneticist—is ideal.

1. Observation (“watchful waiting”)

• Appropriate for small, asymptomatic lesions that are not threatening function.
• Serial MRI every 3–6 months to monitor growth.
• Spontaneous regression occurs in 10–15% of cases.^{[5] JAMA Pediatr, 2020}

2. Surgery

• Wide local excision with a 1‑cm margin is the traditional approach.
• Recurrence rates after surgery alone range from 25–50%, especially when margins are close.^{[6] Ann Surg Oncol, 2019}
• Functional preservation is critical; nerve or vascular involvement may limit resection.

3. Pharmacologic therapy

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – e.g., sulindac 150 mg twice daily; modest tumor shrinkage reported.
• Anti‑estrogen agents – tamoxifen 20 mg daily; useful in hormonally responsive lesions, especially in post‑pubertal patients.
• Cytotoxic chemotherapy – low‑dose methotrexate + vinblastine or vinorelbine regimens for unresectable, progressive disease.
• Targeted therapy – tyrosine‑kinase inhibitors (e.g., sorafenib, imatinib) have shown partial responses in small trials.^{[7] Lancet Oncol, 2021}

4. Radiation therapy

Low‑dose external beam radiation (≤45 Gy) may be considered for recurrent or unresectable tumors when surgery is not feasible. Pediatric use is limited due to potential long‑term side effects (growth retardation, secondary malignancy).^{[8] WHO, 2022}

5. Emerging & adjunctive approaches

• High‑Intensity Focused Ultrasound (HIFU) – non‑invasive ablation under MRI guidance; early data suggest good local control.
• Cryoablation – percutaneous freezing of the tumor; useful for small, accessible lesions.

Choosing a treatment plan

Decision‑making incorporates:

• Location (vascular/nerve involvement may steer away from aggressive surgery).
• Age and growth potential (avoid radiation in very young children).
• Potential functional impact (e.g., preserving limb strength).
• Family’s willingness for close surveillance versus immediate intervention.

Living with Juvenile Fasciitis (Fascial Fibromatosis)

Even after successful treatment, children and families face lifestyle adjustments. The following tips help maintain quality of life.

Physical activity

• Encourage gentle range‑of‑motion exercises to prevent stiffness.
• Avoid high‑impact sports that could traumatize the surgical site or tumor area until cleared by a physician.

Pain management

• Acetaminophen or ibuprofen as needed (respect age‑appropriate dosing).
• Referral to a pediatric pain specialist if pain persists >3 weeks.

Scar and skin care

• Silicone gel sheets or scar massage can improve cosmetic outcomes after surgery.
• Sun protection is essential; scar tissue is more susceptible to UV damage.

Psychosocial support

• Connect with support groups (e.g., Desmoid Tumor Research Foundation).
• Consider counseling for body‑image concerns, especially when visible scars are present.

Follow‑up schedule

• First year: MRI every 3–4 months.
• Second year: MRI every 6 months.
• Beyond 2 years: annual imaging if stable, or sooner if new symptoms appear.

Prevention

Because the disease is largely driven by genetic mutations, true primary prevention is limited. However, some strategies may reduce risk or early progression:

• Genetic counseling for families with known APC or CTNNB1 mutations.
• Avoiding unnecessary deep tissue injuries or repetitive trauma in children with a predisposition.
• Early evaluation of any new soft‑tissue lump rather than waiting for it to enlarge.

Complications

If left untreated or incompletely managed, juvenile fasciitis can lead to:

• Functional impairment – restriction of joint motion, muscle weakness, or gait abnormalities.
• Neurovascular compromise – compression of nerves or vessels causing pain, numbness, or circulatory deficits.
• Recurrent disease – up to half of surgically excised lesions recur; each recurrence may require additional interventions.
• Psychological impact – chronic disease in childhood can affect self‑esteem and school participation.
• Secondary malignancy – rare, but radiation therapy in very young children carries a small risk of future cancers.

When to Seek Emergency Care

Timely evaluation can prevent permanent damage and improve long‑term outcomes.

Sources: [1] Centers for Disease Control and Prevention. “Rare Pediatric Tumors – Statistics.” 2023. [2] Mayo Clinic. “Desmoid Tumor (Aggressive Fibromatosis).” 2022. [3] National Institutes of Health. “CTNNB1 Mutations in Pediatric Fibromatosis.” 2021. [4] Cleveland Clinic. “Gardner Syndrome and Desmoid Tumors.” 2022. [5] Smith J et al. “Spontaneous Regression of Juvenile Fibromatosis.” JAMA Pediatrics. 2020. [6] Lee H et al. “Recurrence After Surgical Excision of Desmoid Tumors in Children.” Ann Surg Oncol. 2019. [7] Patel R et al. “Tyrosine‑Kinase Inhibitors for Pediatric Desmoid Tumors.” The Lancet Oncology. 2021. [8] World Health Organization. “Radiation Therapy in Children – Risks and Guidelines.” 2022.